Stock Analysis of GlycoMimetics Inc (GLYC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code GLYC
Close 0.299
Change 0.0183 / 6.51 %
Volume 2711.27 K
Vol Change 1800.45 K / 197.67 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Low Growth Stock
Value Index Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Mild Stability


Fundamental View of GlycoMimetics Inc
PE (TTM)

-129.45

Very Poor
Price / Book

0.147

Excellent
Price / Sales

482553

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

19300.64 K

Enterprise Value

-41031.97 M

ROA (TTM)

-0.101

Very Poor
ROE (TTM)

-0.114

Very Poor
Net Margin (TTM)

-372775.79

Very Poor
Revenue

13233.33 %

10000.00
Net Profit

59.21 %

-38065.14 K
Debt to Equity

0.0193

Excellent
Altman Z Score

-14.10

Very Poor
Quick Ratio

0

Poor
Cash Ratio

6.11

Excellent


Highs/Lows of GlycoMimetics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.2666 12.30 % 1.54 % 0.310.259217-May-2414-May-24
Two Week1.83 83.64 % 3.42 % 0.420.25606-May-2410-May-24
One Month2.28 86.87 % 5.60 % 2.35770.25618-Apr-2410-May-24
Three Month3.22 90.70 % 5.95 % 3.360.25620-Feb-2410-May-24
Six Months1.45 79.35 % 17.48 % 3.52990.25623-Jan-2410-May-24
One year2.04 85.32 % 27.52 % 3.52990.25623-Jan-2410-May-24
Two year0.63 52.48 % 29.70 % 4.160.25614-Feb-2310-May-24
Five year12.39 97.58 % 85.46 % 4.160.25614-Feb-2310-May-24
Ten year6.48 95.38 % 182.41 % 26.050.25615-Feb-1810-May-24


Technical View of GlycoMimetics Inc
RSI

21.98

Mild Bullish
MACD

-0.555

Bearish
ADX

50.55

Strong Bearish
Super Trend

0.750

Mild Bearish
Williams %R

-97.41

Mild Bullish
CCI

-66.17

Bullish


EMA 5

0.310

Mild Bearish
EMA 15

0.713

Mild Bearish
EMA 50

1.67

Mild Bearish
EMA 100

2.02

Strong Bearish
SMA 100

2.50

Strong Bearish
SMA 200

2.00

Strong Bearish
SMA 5 / 20

0.278 / 1.01

Mild Bearish
SMA 15 / 50

0.760 / 2.00

Strong Bearish
SMA 50 / 200

2.00 / 2.00

Strong Bearish




Charts of GlycoMimetics Inc


Returns of GlycoMimetics Inc with Peers
Period / StockGLYCINDPSTRMAXDX
1 Week12.30%7.44%-5.30%0.204%
1 Mth-86.87%-13.16%-11.51%19.76%
3 Mth-90.70%41.72%-40.39%-25.25%
6mth-79.35%12.14%-4.24%-82.71%
1 Year-85.32%12.68%-79.87%-88.30%
2 Year-52.48%-5.71%-74.72%-85.30%
5 Years-97.58%-99.46%-76.59%-99.54%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of GlycoMimetics Inc with Peers
Ratio / StockGLYCINDPSTRMAXDX
PE-129.45-1.30-0.620-0.190
P/B0.1471.270.878-0.330
ROA-0.101-85.43-76.29-136.03
ROE-0.114-97.78-141.630
Debt To Equity0.01930.00840.562-1.93
Revenue10000.00
13233.33 % 		0
% 		22596.00 K
9.21 % 		12004.00 K
5.87 %
Net Income-38065.14 K
59.21 % 		-15076.47 K
5.26 % 		-18697.00 K
64.31 % 		-63229.00 K
1.18 %


Technicals of GlycoMimetics Inc with Peers
Technical / StockGLYCINDPSTRMAXDX-
ADX50.5517.1011.9213.76
CMF-0.611-0.354-0.101-0.285
MFI25.3766.0121.1439.84
RSI21.9854.1441.4345.33
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MAFalseTrueFalseFalse-


About : GlycoMimetics Inc

Address : 9708 Medical Center Drive, Rockville, MD, United States, 20850
Tel : 240 243 1201
URL : https://www.glycomimetics.com
Code : GLYC, ISIN : US38000Q1022, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 10_Jan_2014
Employee Count : 35

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.


Note : All Data Generated at the End of Trading Hours (EOD Data)